BMY Stock Analysis: Bristol-Myers Squibb | NYSE
Drug Manufacturers - General | NYSE, USA | Market Cap: 129.917m USD | 12M Return: 44.9% | US1101221083 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 494M
EPS Trend: 35.1%
Qual. Beats: 1
Rev. Trend: 92.6%
Qual. Beats: 11
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Bristol-Myers Squibb Company (NYSE: BMY) is a U.S.-based global biopharmaceutical company headquartered in Princeton, New Jersey. Founded in 1887, the company discovers, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products worldwide, operating within the Health Care sector and the Pharmaceuticals sub-industry.
The company maintains a diversified portfolio spanning oncology, hematology, immunology, cardiovascular, and neuroscience therapeutic areas. Its oncology franchise includes key drugs such as Opdivo (an anti-PD-1 immunotherapy), Yervoy, Opdualag, Breyanzi, Abecma, Krazati, Augtyro, and Abraxane. Immunology offerings include Orencia, Zeposia, Sotyktu, and Cobenfy, while its cardiovascular and hematology products include Eliquis, Camzyos, Reblozyl, Revlimid, Pomalyst/Imnovid, and Sprycel.
Like most large-cap pharmaceutical companies, BMY relies on a wholesale and specialty distribution model, selling its products through wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. This distribution structure reflects the sectors typical reliance on third-party intermediaries to reach both patients and providers across multiple regions.
The company maintains strategic collaborations with smaller biotechnology firms to expand its pipeline, including a partnership with Arcus Biosciences focused on developing novel treatments for kidney cancer. Such licensing and collaboration agreements are common within the biopharmaceutical industry, allowing large-cap companies to access innovation from smaller research-focused partners without bearing the full cost of early-stage drug discovery.
- Eliquis Medicare price negotiations and patent cliff pressure 2026 revenue
- Cobenfy schizophrenia launch drives neuroscience segment revenue growth
- High acquisition debt weighs on margins and capital returns
| Net Income: 9.28b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA -2.34 > 1.0 |
| NWC/Revenue: 20.17% < 20% (prev 11.94%; Δ 8.23% < -1%) |
| CFO/TA 0.15 > 3% & CFO 12.8b > Net Income 9.28b |
| Net Debt (34.0b) to EBITDA (16.7b): 2.04 < 3 |
| Current Ratio: 1.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.05b) vs 12m ago 0.49% < -2% |
| Gross Margin: 70.16% > 18% (prev 65.21%; Δ 4.95% > 0.5%) |
| Asset Turnover: 53.96% > 50% (prev 50.39%; Δ 3.57% > 0%) |
| Interest Coverage Ratio: 7.88 > 6 (EBIT TTM 13.6b / Interest Expense TTM 1.73b) |
| A: 0.11 (Total Current Assets 28.6b - Total Current Liabilities 18.7b) / Total Assets 87.6b |
| B: 0.23 (Retained Earnings 20.3b / Total Assets 87.6b) |
| C: 0.15 (EBIT TTM 13.6b / Avg Total Assets 91.2b) |
| D: 0.34 (Book Value of Equity 22.3b / Total Liabilities 65.3b) |
| Altman-Z'' = 2.86 = A |
| DSRI: 0.68 (Receivables 10.6b/15.1b, Revenue 49.2b/47.7b) |
| GMI: 0.93 (GM 65.21% / 70.16%) |
| AQI: 1.05 (AQ_t 0.58 / AQ_t-1 0.56) |
| SGI: 1.03 (Revenue 49.2b / 47.7b) |
| TATA: -0.04 (NI 9.28b - CFO 12.8b) / TA 87.6b) |
| Beneish M = -3.31 (Cap -4..+1) = AA |
As of September 20, 2026, the stock is trading at USD 63.06 with a total of 36,831,221 shares traded. Over the past week, the price has changed by -0.91%, over one month by -4.53%, over three months by +18.10% and over the past year by +44.93%.
Current recommended Stop Loss: 61.20 (which is 2.9% or 1.3 ATR below the current price).
Bristol-Myers Squibb has received a consensus analysts rating of 3.48. Therefore, it is recommended to hold BMY.
- StrongBuy: 6
- Buy: 4
- Hold: 18
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 66.4 | 5.3% |
P/E Trailing = 14.0088
P/E Forward = 9.7561
P/S = 2.6413
P/B = 5.8328
P/EG = 17.7447
Revenue TTM = 49.2b USD
EBIT TTM = 13.6b USD
EBITDA TTM = 16.7b USD
Long Term Debt = 42.1b USD (from longTermDebt, last quarter)
Short Term Debt = 1.03b USD (from shortTermDebt, last quarter)
Debt = 45.1b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.93b
Net Debt = 34.0b USD (calculated: Debt 45.1b - CCE 11.1b)
Enterprise Value = 164b USD (130b + Debt 45.1b - CCE 11.1b)
Interest Coverage Ratio = 7.88 (Ebit TTM 13.6b / Interest Expense TTM 1.73b)
EV/FCF = 14.33x (Enterprise Value 164b / FCF TTM 11.4b)
FCF Yield = 6.98% (FCF TTM 11.4b / Enterprise Value 164b)
FCF Margin = 23.26% (FCF TTM 11.4b / Revenue TTM 49.2b)
Net Margin = 18.87% (Net Income TTM 9.28b / Revenue TTM 49.2b)
Gross Margin = 70.16% ((Revenue TTM 49.2b - Cost of Revenue TTM 14.7b) / Revenue TTM)
Gross Margin QoQ = 71.28% (prev 70.22%)
Tobins Q-Ratio = 1.87 (Enterprise Value 164b / Total Assets 87.6b)
Interest Expense / Debt = 3.84% (Interest Expense 1.73b / Debt 45.1b)
Taxrate = 22.12% (2.63b / 11.9b)
NOPAT = 10.6b (EBIT 13.6b * (1 - 22.12%))
Current Ratio = 1.53 (Total Current Assets 28.6b / Total Current Liabilities 18.7b)
Debt / Equity = 2.02 (Debt 45.1b / totalStockholderEquity, last quarter 22.3b)
Debt / EBITDA = 2.04 (Net Debt 34.0b / EBITDA 16.7b)
Debt / FCF = 2.97 (Net Debt 34.0b / FCF TTM 11.4b)
Total Stockholder Equity = 19.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.18% (Net Income 9.28b / Total Assets 87.6b)
RoE = 46.75% (Net Income TTM 9.28b / Total Stockholder Equity 19.9b)
RoCE = 22.01% (EBIT 13.6b / Capital Employed (Equity 19.9b + L.T.Debt 42.1b))
RoIC = 15.72% (NOPAT 10.6b / Invested Capital 67.5b)
WACC = 5.59% (E(130b)/V(175b) * Re(6.49%) + D(45.1b)/V(175b) * Rd(3.84%) * (1-Tc(0.22)))
Discount Rate = 6.49% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.07 | Cagr: 0.55%
[DCF] Terminal Value 73.10% ; FCFF base≈12.7b ; Y1≈11.1b ; Y5≈8.99b
[DCF] Fair Price = 54.04 (EV 144b - Net Debt 34.0b = Equity 110b / Shares 2.04b; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 35.09 | EPS CAGR: 42.04% | SUE: 3.45 | # QB: 1
Revenue Correlation: 92.61 | Revenue CAGR: 3.16% | SUE: 4.0 | # QB: 11
EPS current Quarter (2026-09-30): EPS=1.73 | Chg30d=-0.06% | Revisions=+75% | Analysts=20
EPS current Year (2026-12-31): EPS=6.95 | Chg30d=+0.04% | Revisions=+89% | GrowthEPS=+13.0% | GrowthRev=+3.4%
EPS next Year (2027-12-31): EPS=6.56 | Chg30d=+0.12% | Revisions=+76% | GrowthEPS=-5.6% | GrowthRev=-3.4%
[Analyst] Revisions Ratio: +87% (up=65, down=3)